SPOTLIGHT -
EP. 1: Overview of Beta Thalassemia
EP. 2: Prevalence and Clinical Presentation of B-Thalassemia
EP. 3: β-Thalassemia Severity and Impact on Patients
EP. 4: Impact of β-Thalassemia on the Providers
EP. 5: Current Approaches for Beta-Thalassemia
EP. 6: The Role of Transfusion for Beta-Thalassemia
EP. 7: Understanding Transfusion for Beta-Thalassemia
EP. 8: Iron Dysregulation & Allogeneic Stem Cell Transplantation
EP. 9: Approval of Novel Therapy for Beta-Thalassemia
EP. 10: End Points of Phase III Study for Beta-Thalassemia
EP. 11: Future Impact of the Novel Therapy for Beta-Thalassemia
EP. 12: The Potential for Gene Therapy in Beta-Thalassemia
EP. 13: The Process for Gene Therapy in Beta-Thalassemia
EP. 14: The Cost and Safety of Gene Therapy in Beta-Thalassemia
EP. 15: Pipeline Agents for the Treatment of Beta-Thalassemia
EP. 16: Final Thoughts on the Treatment of Beta-Thalassemia
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
